ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. ARCA’s principal focus is to develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, and clinical development. 
TypePublic
HQWestminster, US
Founded2009
Size (employees)20 (est)
Websitearcabio.com
ARCA biopharma was founded in 2009 and is headquartered in Westminster, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

ARCA biopharma Office Locations

ARCA biopharma has offices in Westminster and Aurora
Westminster, US (HQ)
140 11080 Circle Point Rd
Aurora, US
12635 E. Montview Blvd
Westminster, US
11080 CirclePoint Rd Ste 140
Show all (3)
Report incorrect company information

ARCA biopharma Financials and Metrics

ARCA biopharma Revenue

USD

Net income (Q2, 2018)

(4.9m)

EBIT (Q2, 2018)

(4.9m)

Market capitalization (18-Oct-2018)

8.8m

Closing stock price (18-Oct-2018)

0.6

Cash (30-Jun-2018)

9.6m
ARCA biopharma's current market capitalization is $8.8 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

4.6m

R&D expense

14.1m

Operating expense total

18.7m

EBIT

(18.7m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

General and administrative expense

1.0m950.0k1.1m2.1m

R&D expense

1.4m1.3m1.7m2.9m

Operating expense total

2.4m2.3m2.8m4.9m

EBIT

(2.4m)(2.3m)(2.8m)(4.9m)
Annual
USDFY, 2016FY, 2017

Cash

7.4m8.7m

Current Assets

21.4m12.3m

PP&E

66.0k42.0k

Total Assets

24.6m12.4m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Cash

19.4m17.2m12.2m44.1m41.5m29.7m14.4m8.1m6.2m12.1m9.6m

Current Assets

19.7m17.5m12.7m44.3m41.7m31.0m26.7m23.8m19.9m12.7m10.0m

PP&E

29.0k26.0k34.0k34.0k31.0k24.0k76.0k69.0k59.0k37.0k33.0k

Total Assets

20.5m18.0m13.3m45.1m42.4m36.9m32.6m28.7m20.6m12.8m10.1m
Annual
USDFY, 2016FY, 2017

Net Income

(16.4m)(18.5m)

Depreciation and Amortization

24.0k27.0k

Accounts Payable

841.0k(583.0k)

Cash From Operating Activities

(15.0m)(17.5m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(4.8m)(7.1m)(2.7m)(5.5m)(8.3m)(3.6m)(7.5m)(12.2m)(4.3m)(2.7m)(4.9m)

Depreciation and Amortization

5.0k8.0k4.0k9.0k14.0k5.0k9.0k17.0k7.0k6.0k11.0k

Accounts Payable

128.0k(232.0k)(144.0k)(198.0k)(167.0k)380.0k391.0k648.0k(234.0k)(14.0k)(217.0k)

Cash From Operating Activities

(5.4m)(7.5m)(3.1m)(5.5m)(7.9m)(3.9m)(7.4m)(11.1m)(4.3m)(3.1m)(5.3m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

ARCA biopharma News and Updates

ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update

End-of-Phase 2 Meeting with the U.S. FDA on Gencaro Atrial Fibrillation Development Plan Completed; Single Additional Phase 3 Trial Planned to Support NDA Submission End-of-Phase 2 Meeting with the U.S. FDA on Gencaro Atrial Fibrillation Development Plan Completed; Single Additional Phase 3 Trial Pl…
Report incorrect company information

ARCA biopharma Company Life and Culture

Report incorrect company information